Kadcyla 160 mg Injection is a prescription cancer medicine that contains ado-trastuzumab emtansine. It is used to treat HER2-positive breast cancer that has either spread to other parts of the body or has not responded well to earlier treatments. Kadcyla combines two medicines in one: trastuzumab, which targets the HER2 protein on cancer cells, and emtansine, a chemotherapy drug that helps destroy those cells from the inside.

This medicine is used in both early and advanced stages of breast cancer, including cases where the cancer comes back within six months of completing chemotherapy. Kadcyla works specifically against tumors that produce higher-than-normal levels of the HER2 protein, helping slow down cancer growth and improve treatment outcomes.

Some patients may still have cancer remaining after chemotherapy and HER2-targeted treatment, which can affect recovery. It’s important to tell your doctor right away if you notice symptoms such as allergic reactions or unusual bleeding. Kadcyla generally does not affect kidney function, though infusion-related reactions can rarely occur. Common side effects include nausea, vomiting, diarrhea, and hair loss, which are usually mild and manageable under medical care.

Ado-trastuzumab emtansine works by targeting HER2-positive cancer cells and delivering chemotherapy directly inside them. This helps destroy cancer cells from within, slow tumor growth, and reduce tumor size while limiting damage to healthy cells.

Side Effects of Kadcyla 160 mg Injection

Like all medications, Kadcyla 160 mg Injection may cause side effects. However, not everyone will experience them.

Serious Side Effects (Seek immediate medical attention):

• Liver problems (raised liver enzymes, jaundice)
• Heart problems (reduced heart function, shortness of breath)
• Low platelet count, leading to unusual bleeding or bruising
• Severe allergic or infusion-related reactions
• Lung problems (cough, difficulty breathing)
• Nerve damage causing numbness or tingling in hands and feet

Note: Always consult your doctor if you experience any unusual symptoms or if common side effects become severe.

Common Side Effects (Usually mild and temporary):

These are usually mild to moderate and may improve as your body adjusts to the treatment:

• Nausea or vomiting
• Fatigue or tiredness
• Diarrhea or constipation
• Headache
• Muscle or joint pain
• Hair thinning or hair loss
• Mouth sores
• Decreased appetite

Kadcyla 160 mg Injection is given as an intravenous infusion by a trained healthcare professional in a hospital or clinic. The dosage is based on the patient’s body weight, overall health, and response to treatment, and it is usually administered once every three weeks. Your doctor may adjust the dose or delay treatment depending on side effects, so it is important to follow the prescribed treatment schedule closely.

Breast Feeding

Unsafe

Breastfeeding is not recommended during treatment with Kadcyla and for at least 7 months after the final dose, as the medicine may pass into breast milk and harm the baby.

Alcohol

Consult Your Doctor

Alcohol should be consumed with caution during treatment, as Kadcyla can affect liver function and alcohol may increase the risk of liver-related side effects. It is best to consult your doctor before drinking alcohol.

Lungs

Unsafe

Kadcyla may rarely cause lung-related problems such as inflammation or breathing difficulty. Inform your doctor immediately if you experience persistent cough, shortness of breath, or chest discomfort.

Driving

Unsafe

Kadcyla can cause fatigue, dizziness, or weakness in some patients. Avoid driving or operating heavy machinery if you do not feel fully alert after receiving the injection.

Pregnancy

Unsafe

Kadcyla should not be used during pregnancy as it may harm the unborn baby. Women of childbearing potential should use effective contraception during treatment and for several months after the last dose, as advised by the doctor.

Kadcyla 160 mg Injection is used to treat HER2-positive breast cancer, including early-stage disease with residual cancer and advanced or metastatic breast cancer.

Kadcyla 160 mg Injection targets HER2-positive cancer cells and delivers chemotherapy directly inside them, helping destroy cancer cells while limiting damage to healthy tissue.

It is given as an intravenous (IV) infusion by a healthcare professional, usually once every 3 weeks.

Common side effects include nausea, fatigue, diarrhea, hair thinning, muscle or joint pain, and low platelet counts.

No. Kadcyla 160 mg Injection can harm an unborn baby and should not be used during pregnancy. Breastfeeding should be avoided during treatment and for several months after the last dose.

Regular tests are needed to monitor heart function, liver health, and blood counts throughout treatment.

Kadcyla 160mg Injection (Ado-Trastuzumab Emtansine) is available through Phoenix Pharmex for patients, caregivers, and healthcare providers across India. As a trusted supplier, distributor, and wholesaler, we offer genuine Kadcyla Injection with prescription verification and cold-chain delivery. Kadcyla 160mg price varies by pack size and availability contact us for current pricing.

The information on the Phoenix Pharmex website is shared for educational purposes only and is not a substitute for professional medical advice or treatment. Always consult a doctor for any health-related questions. Please avoid self diagnosis or delaying medical care based on this content. Our mission is to support informed decisions not replace professional medical guidance.